Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Secondary Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Secondary Neoplasm

Cancer Family

Secondary Neoplasm

CI-CAN-00000050Explore in graph →

Non-malignant4,276 active trials56 approved drugs532 evidence items

NCIt: C36255

Overview
Statistics
Survival
Genomics199
Variants & evidence532
Drugs130
Trials14673
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (486)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 301–325 of 486 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.
· Clin Lung Cancer · 2015 · PMID 25769807 · validated civic_curation pubmed
Somatic mutations of von Hippel-Lindau (VHL) tumor-suppressor gene in European kidney cancers.
· Int J Cancer · 1995 · PMID 7591282 · validated civic_curation pubmed
Mutations of the VHL tumour suppressor gene in renal carcinoma.
· Nat Genet · 1994 · PMID 7915601 · validated civic_curation pubmed
Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor.
· Cold Spring Harb Mol Case Stud · 2019 · PMID 31160355 · validated civic_curation pubmed
[A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents].
· Hinyokika Kiyo · 2013 · PMID 23995526 · validated civic_curation pubmed
Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature.
· J Clin Pathol · 2023 · PMID 34583947 · validated civic_curation pubmed
NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
· Mod Pathol · 2020 · PMID 31375766 · validated civic_curation pubmed

Showing 301–325 of 486 publications

← Previous
1
…
12
13
14
…
20
Next →

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

· Sci Transl Med · 2010 · PMID 21160078 · validated civic_curation pubmed

Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.

· EMBO Mol Med · 2016 · PMID 26758680 · validated civic_curation pubmed

The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

· Cell · 2012 · PMID 22541434 · validated civic_curation pubmed

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

· Nat Med · 2008 · PMID 19029981 · validated civic_curation pubmed

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

· Cancer Res · 2014 · PMID 24240700 · validated civic_curation pubmed

Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers.

· Cancer Cell · 2011 · PMID 21840482 · validated civic_curation pubmed

Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.

· Cell Cycle · 2014 · PMID 24841718 · validated civic_curation pubmed

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

· Cancer Cell · 2016 · PMID 26725216 · validated civic_curation pubmed

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

· Clin Cancer Res · 2017 · PMID 27663592 · validated civic_curation pubmed

Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.

· Oncotarget · 2016 · PMID 26701727 · validated civic_curation pubmed

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.

· Clin Cancer Res · 2010 · PMID 20453058 · validated civic_curation pubmed

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

· Cancer Res · 2017 · PMID 28490518 · validated civic_curation pubmed

Drug-sensitive FGFR3 mutations in lung adenocarcinoma.

· Ann Oncol · 2017 · PMID 27998968 · validated civic_curation pubmed

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

· Cancer Res · 2008 · PMID 19010894 · validated civic_curation pubmed

Characterization of rare transforming KRAS mutations in sporadic colorectal cancer.

· Cancer Biol Ther · 2014 · PMID 24642870 · validated civic_curation pubmed

Anti-tumor activity of motesanib in a medullary thyroid cancer model.

· J Endocrinol Invest · 2012 · PMID 21422803 · validated civic_curation pubmed

AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.

· PLoS One · 2012 · PMID 23056499 · validated civic_curation pubmed

TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.

· Oncogene · 2010 · PMID 19966866 · validated civic_curation pubmed